Amit Goyal, MD

DocwireNews

A high-quality, large-scale network meta-analysis found, yet again, that intravascular imaging to guide percutaneous coronary intervention (PCI) improves hard clinical end points. The results are definitive and strongly advocate for imaging-guided PCI.The 2021 American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) guidelines for coronary artery revascularization give a class 2a recommendation to considering the use of intravascular ultrasound in patients with intermediate stenosis of the left main artery to help define lesion severity. Yet these already outdated guidelines stop short of recommending routine use of intracoronary imaging to guide and optimize PCI. In addition, the use of intracoronary imaging in clinical practice remains low, likely due to a combination of cost versus reimbursement calculations, perceived increase in procedural time, technical inexperience, and disbelief in the benefits. Some operators doggedly maintain a self-assured conviction of the superiority of their own angiographic estimations to guide PCI. Well, it may be time to change all that.Kuno and colleagues performed a network meta-analysis of 32 randomized controlled trials investigating outcomes with intravascular imaging-guided, functionally guided, or angiography-guided PCI. In an analysis that included 22,684 patients, they compared the 3 approaches with respect to the primary outcome of trial-defined major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction (MI), and target lesion revascularization (TLR), as well as several secondary outcomes. Of the 32 trials, 19 studied PCI in the setting of acute coronary syndrome (ACS) and 13 were non-ACS trials. Mean follow-up ranged from 6 months to 5 years.Compared with angiography-guided PCI, imaging guidance led to significant reductions in the risk for all major outcomes tested&mdash;MACE (relative risk [RR], 0.72; 95% CI, 0.62-0.82), cardiovascular death (RR, 0.56; 95% CI, 0.42-0.75), MI (RR, 0.81; 95% CI, 0.66-0.99), stent thrombosis (RR, 0.48; 95% CI, 0.31-0.73), and TLR (RR, 0.75; 95% CI, 0.57-0.99). The use of functional testing to guide PCI significantly reduced the risk of MACE (RR, 0.81; 95% CI, 0.69-0.96) and MI (RR, 0.78; 95% CI, 0.63-0.96) but not the risk of cardiovascular death, stent thrombosis, or TLR when compared with angiography guidance. While there were no significant differences in imaging versus functional guidance for the individual end points, intravascular imaging ranked best for MACE, cardiovascular death, stent thrombosis, and TLR. The supremacy of imaging guidance was consistent in both the ACS and non-ACS groups, though the benefit of imaging was exaggerated in the ACS trials.The message here is clear and consistent with troves of prior data that strongly support the routine use of intravascular imaging to guide PCI. Improvements in hard end points across the board likely reflect improved stent sizing and optimization. In truth, maximizing the benefit from imaging guidance likely should entail both pre-PCI (to understand lesion morphology and determine appropriate treatment length and diameter) and post-PCI (to assess for edge dissections, stent-vessel apposition, and expansion) imaging. The implications of imaging &ldquo;ranking&rdquo; better than functional testing are unclear for practice. Intracoronary imaging and functional testing serve different purposes. The combination of functional testing to guide the decision to perform or defer PCI with imaging to guide and optimize PCI is likely the best approach moving forward.The ACC/AHA/SCAI guidelines for coronary artery revascularization already give a strong class 1 recommendation for the use of functional testing with fractional flow reserve or instantaneous wave-free ratio to guide the decision to proceed with PCI. The results of this meta-analysis build on an already robust database and may very well catapult routine use of intracoronary imaging from a class 2a recommendation for the left main artery to a class 1 recommendation for any coronary artery. Reimbursement paradigms may need to shift in order to help drive practice change and improve patient outcomes. The results (should) speak for themselves.SourcesKuno T, Kiyohara Y, Maehara A, et al. Comparison of intravascular imaging, functional, or angiographically guided coronary intervention. J Am Coll Cardiol. 2023;82(23):2177-2178. doi:10.1016/J.JACC.2023.09.823Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022. doi:10.1161/CIR.0000000000001038

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Intravascular Imaging Improves PCI Outcomes, Period

Interventional Cardiology

Intravascular imaging to guide PCI improves hard clinical end points.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe